Title Sporton (6146 TT) Buy, TP: NT$200
  ESG Equity Note: TXC (3042 TT) Buy, TP: NT$74
  Pacific Hospital Supply (4126 TT) Buy, TP: NT$95
  ESG Equity Note: PCSC (2912 TT) Buy, TP: NT$95
  ESG Equity Note: TSMC (2330 TT) Buy, TP: NT$376
  Largan (3008 TT) Buy, TP: NT$4,570
  ESG Equity Note: Accton (2345 TT) Buy, TP: NT$191
  Sinbon (3023 TT) Buy, TP: NT$138
  ESG Equity note: Asia Cement (1102 TT) Buy, TP: NT$52
  Equity Note: Kinsus (3189 TT) Buy, TP: NT$50
More Titles
Title:Sporton (6146 TT) Buy, TP: NT$200
Download File:6146 TT Sporton note 200421--sinopac.pdf 
Summary:Lower TP by 8% to NT$200 (25x 2020F P/E); Maintain Buy: 1) Sportoní»s 2019 sales arrived in line at NT$2.99bn (-0.4%); its EPS were flattish at NT$7.27, as 5G related demand is still too small to offset 4G handset market maturity; 2) Sporton expects 5G handset penetration to grow from 10-20% in 2020 to 20-40% in 2021. Since ASP testing for 5G handsets is 50-100% higher than for 4G ones, handset testing GM will rise. We expect Sporton will leverage its strengths to gain market share in 5G testing. We estimate 2020/2021 sales at NT$3.27bn (+9.4% YoY)/NT$3.85bn (+17.8% YoY), and EPS at NT$7.89/NT$9.83.
Register online at Become Member to receive Taiwan research services. For more information, contact TaiwanResearch.com. Tel (8862) 2316-5181
©2001, 2000, 1999 SinoPac All rights reserved. Additional copyright information applies.